Alzecure completes transaction with Lilly

Eli Lilly (LLY) received UK approval for its oral GLP-1 drug, Foundayo, for weight management and type 2 diabetes, marking its first European regulatory win. This follows Novo Nordisk's (NVO) earlier approval of its oral Wegovy in the UK and EU. Foundayo's once-daily, no-restriction design may offer a competitive advantage. Both companies are expanding in the growing weight loss drug market.

Moderna and Merck's experimental cancer vaccine showed promising Phase 3 results, preventing melanoma recurrence in certain patients. This drove significant stock price increases for both companies and other biopharma stocks, including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and BioNTech. Moderna's shares surged 138%, while Merck's rose 12.4%. The broader biopharma sector has been on an upswing, with investors rotating away from tech stocks. President Trump's nomination of a new FDA commiss

Eli Lilly shares closed 1.9% below their all-time high after a 3.6% rise. Q2 revenue surged 48% to $22.97B, with volume up 60% but prices down 13%. Mounjaro and Zepbound contributed 64% of sales. Lilly raised its 2026 revenue outlook to $85B-$87B. Competition and pricing pressures remain key concerns.

Eli Lilly (LLY) reported strong Q2 2026 results, with Mounjaro and Zepbound generating $9.94B and $4.93B respectively, up 91% and 46% YoY. Novo Nordisk (NVO) saw flat sales for Ozempic and Wegovy. Lilly's Foundayo, though early, shows growth potential. Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are developing competing oral GLP-1 drugs. LLY stock is up 14% YTD, trading at a higher P/E than its industry.

Eli Lilly's stock rose 5.8% after Q2 results beat expectations, with revenue up 48% YoY to $22.97B and adjusted EPS up 33% to $8.38. GLP-1 drugs Mounjaro and Zepbound drove growth, contributing 65% of revenue. Lilly raised its sales forecast and highlighted strong pipeline prospects, including new obesity treatments and next-gen GLP-1 therapies.

Eli Lilly (LLY) stock rose 5% to a 52-week high after weekly prescription data showed its obesity pill Foundayo gained 14% in prescriptions, while Novo Nordisk's Wegovy fell 5%. Lilly also announced two pipeline deals, including a $1B+ Alzheimer's drug acquisition, reinforcing its bullish outlook. The stock's gain was driven by company-specific news, with broader market indices showing minimal movement.